If you are looking for clues telling you which stocks have a good chance of increasing in value, you might want consider watching what insiders are doing. After all, talk is cheap, but when insiders put their own money on the line, you should sit up and take note.

Take-Two Interactive Software Inc (TTWO) topped the insider-buying charts for the week ending July 9 as insiders snapped up 427,900 shares of company stock at a market value of $4,093,939. During the past six months, insiders have increased their overall holdings in the company by 64.15% and now own 2.74% of TTWO stock.

Continue reading Insiders Snapping Up Take-Two Interactive, Icahn Enterprises and More

Insiders Snapping Up Take-Two Interactive, Icahn Enterprises and More originally appeared on BloggingStocks on Tue, 21 Sep 2010 12:20:00 EST. Please see our terms for use of feeds.

If you are looking for clues telling you which stocks have a good chance of increasing in value, you might want consider watching what insiders are doing. After all, talk is cheap, but when insiders put their own money on the line, you should sit up and take note.

Trius Therapeutics Inc (TSRX) topped the insider-buying charts for the week ending July 9th as insiders snapped up 3,001,859 shares of company stock at a market value of $15,009,295. During the past six months, insiders have increased their overall holdings in the company by 354.34% and now own 57.55% of TSRX stock.

Medicines Co (MDCO) was not far behind, with insiders buying 667,040 shares at a market value of $8,037,832. Insiders now own 1.43% of the company's stock after decreasing their overall holdings by -4.17% during the past six months.

Continue reading Insiders Snapping Up Trius Therapeutics, Medicines Co and More

Insiders Snapping Up Trius Therapeutics, Medicines Co and More originally appeared on BloggingStocks on Mon, 16 Aug 2010 14:40:00 EST. Please see our terms for use of feeds.

• PDUFA date for Genentech, Inc. (NYSE: DNA) and Roche Holding Ltd. (OTC: RHHBY)'s supplemental Biologics License Application for Herceptin for label expansion to include AC followed by docetaxel in treatment of adjuvant HER2+ breast cancer.
• PDUFA date for Shire plc (NASDAQ: SHPGY) and New River Pharma's supplemental New Drug Application for Vyvanse (NRP-104) treatment of Attention Deficit Hyperactivity Disordre, or ADHD, in adult patients 18-55 years old; the drug is already approved for pediatric ADHD ages 6-12.
• Verizon Communications Inc. (NYSE: VZ) to report Q earnings; conference call at 8:30am.
• Tyson Foods, Inc. (NYSE: TSN) to report Q2 earnings; conference call at 9:00am.

• Two-day FOMC meeting beginning at 8:30am.
• PDUFA date for Merck & Co., Inc. (NYSE: MRK)'s New Drug Application for Cordaptive (MK-0524A) adjunctive therapy to diet for treating elevated LDL Cholesterol, low HDL Cholesterol and elevated triglycerides levels.
  
• PDUFA date for Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP)'s supplemental New Drug Application for dose of 8mg treatment of Irritable Bowel Syndrome with Constipation; already approved for Chronic Idiopathic Constipation at 24ug dosage.
• BP plc (NYSE: BP) to report Q1 earnings; conference call at 10:15am.
• United States Steel Company (NYSE: X) to report Q1 earnings; conference call at 2:00pm.

Continue reading Market highlights for next week: Two-day FOMC meeting

Market highlights for next week: Two-day FOMC meeting originally appeared on BloggingStocks on Fri, 25 Apr 2008 16:37:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Oppenheimer upgraded shares of Valueclick (NASDAQ:VCLK) to Outperform from Perform following the company's Q4 upside, as they believe the FTC investigation completed with no material penalties and that lead generation is stabilizing.
  
• Citigroup upgraded shares of The Medicines Co (NASDAQ:MDCO) to Buy from Hold following the solid Q4 results to reflect a better risk/reward profile and stabilizing PCI volume.
  
• Goldman raised its rating on British Sky Broadcasting (NYSE:BSY) to Buy from Sell and added shares to their Conviction Sell List as they see above-average upside at tough valuations.

• Goldman upgraded the U.S. Trucking Sector to Attractive from Cautious, also upgraded YRC Worldwide (NASDAQ:YRCW) and Arkansas Best (NASDAQ:ABFS) to Neutral from Sell.
  
• ING upgraded Novartis (NYSE:NVS) to Buy from Hold.

Analyst upgrades: VCLK, MDCO and BSY originally appeared on BloggingStocks on Thu, 14 Feb 2008 10:48:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Hambrecht upgraded shares of Seagate Tech (NYSE: STX) on improving demand and second half of 2007 prospects. Bear Stearns upgraded shares to Outperform from Peer Perform based on stabilizing industry conditions.

• ING upgraded shares of SAP AG (NYSE: SAP) to Buy from Hold shares to reflect the migration within the company's large installed base and growing opportunities in the small business market.

• Hambrecht upgraded Western Digital (NYSE: WDC) to Buy from Hold on improving demand for 2H07 growth prospects.

• HSBC raised BAE Systems (OTC: BAESY) off the ground, upgrading shares to Neutral from Underweight.

• Banc of America upgraded Manpower (NYSE: MAN) to Buy from Neutral to reflect the change in French payroll tax subsidies, which they view as a positive change to the company's ongoing margin structure.

• First Albany upgraded ATMI Inc (NASDAQ: ATMI) to Buy from Hold.

• The Medicines Co (NASDAQ: MDCO) was raised to Sector Perform from Underperform at RBC Capital.

• Sonic Solutions (NASDAQ: SNIC) was upgraded to Buy from Hold at Kaufman.

• ThinkEquity upgraded Interwoven (NASDAQ: IWOV) to Accumulate from Source of Funds.

• BB&T upgraded Omnicell (NASDAQ: OMCL) to buy from Hold.

Analyst upgrades 7-20-07: BAESY, MDCO, STX and WDC originally appeared on BloggingStocks on Fri, 20 Jul 2007 11:04:00 EST. Please see our terms for use of feeds.

Medicines Co (NASDAQ: MDCO) volatility spikes on hope for patent extension and 7/25 EPS.

• MDCO is a developer of products to improve acute hospital care and Angiomax; a treatment to clear restricted blood vessels near the heart.
  
• MDCO will announce EPS on July 25th.
  
• RBC Capital says: "It appears that an amendment to the Senate version of the pending Patent Reform Act contains language granting the USPTO discretion to accept late filings for patent extension. This gives MDCO a potential path to gaining patent extension beyond its 2010 expiration."
  
• MDCO August option implied volatility of 78 is above its 26-week average of 43 according to Track Data, suggesting larger price fluctuations.

Caterpillar (NYSE: CAT) volatility elevated after EPS of $1.24.

• CAT reported second-quarter sales and revenues of $11.3 billion and a profit of $823 million.
  
• Smith Barney says: "Overall, stock is going to get hit hard today as earnings power is back to 'believe me' story about operational performance."
  
• CAT overall option implied volatility of 30 is above its 26-week average of 25 according to Track Data, suggesting larger risk.

Daily Option Update is provided by Stock Options Specialist Paul Foster of theflyonthewall.com.

Option update 7-20-07: Medicines Co volatility spikes on hope for patent extension & 7/25 EPS originally appeared on BloggingStocks on Fri, 20 Jul 2007 10:30:00 EST. Please see our terms for use of feeds.